Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC)
(Delayed Data from NSDQ)
$5.80 USD
-0.08 (-1.28%)
Updated May 3, 2019 03:29 PM ET
After-Market: $5.88 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[TLC]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Industry: Medical - Drugs
Going Private, But Perhaps Just For Now; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 10.00
Industry: Medical - Drugs
TLC599 OA Phase 3 Data in 4Q; ?590 EOP2 Meeting in June; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
2020 Results; TLC599 OA Phase 3 Enrolled and We Project 4Q Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
3Q20: TLC599 Enrollment Completion Expected by Year-End; End-21 Data; Other Pipeline Is Potential Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
2Q20: TLC599 Enrollment on Track for End-2021 Data; Await More ?590 Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
TLC590 Bunionectomy Phase 2 Enrolls Ahead of Schedule; Expect 2Q Data; Potential Upside to Our Model; Raise to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
3Q19 Results; TLC599 Phase 3 Underway; TLC590 Data by mid-2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Highlighting Early-Stage Oncology Candidate at ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
2Q19 Results; TLC599 and TLC590 Advancing After Financing
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
1Q19 Results; TLC590 Preliminary Data, and TLC599 Phase 3 Initiation Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
TLC599 for Knee OA: Only a Single Phase 3 Required; Longer Study Incorporates Repeat Dosing; ?590 Bunionectomy Data Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Potential 4 to 7 Day Post-Surgical Pain Relief?; Raise to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: MAHER H
Price: 25.00
Industry: Medical - Drugs
TLC590 Post-Op Pain Candidate - Potential Upside to Our Model - Phase 1/2 Enrolled; Data 1Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 25.00
Industry: Medical - Drugs
Liposomal Drug Delivery: Faster, Longer, or Stronger Therapies; Initiate With Buy and $9 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Price: 75.00
|
|